ropinirole has been researched along with quinelorane in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allerton, CM; Batchelor, DV; Baxter, AD; Blagg, J; Burring, DJ; Carr, CL; Cook, AS; Nichols, CL; Phipps, J; Sanderson, VG; Verrier, H; Wong, S | 1 |
| Capuano, B; Jörg, M; Lee, KC; Mak, FS; May, LT; Miller, ND; Scammells, PJ | 1 |
| Hiratochi, M; Ijiro, T; Kaidoh, K; Oana, F; Suzuki, T; Tsuchioka, A; Yamauchi, Y | 1 |
3 other study(ies) available for ropinirole and quinelorane
| Article | Year |
|---|---|
Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
Topics: Administration, Intranasal; Animals; Crystallography, X-Ray; Dogs; Dopamine Agonists; Drug Design; Humans; Models, Molecular; Molecular Structure; Rats; Receptors, Dopamine D3; Stereoisomerism; Structure-Activity Relationship | 2007 |
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Blood-Brain Barrier; CHO Cells; Cricetulus; Dopamine Agonists; Ligands; Male; Rats; Rats, Wistar; Receptors, Dopamine D2 | 2015 |
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Ergolines; Indoles; Injections, Intraventricular; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Quinolines; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 2015 |